New

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to intervention is critical when working with diabetic clients. The benefit of doing so in improved outcomes for both type 1 and type 2 diabetes has been clearly established by clinical trials conducted in both the U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for p...

New Advances in Gastric Diagnostics: Smaller is Better

In recent years, miniaturization has opened up exciting possibilities in the area of gastric diagnostics. New technology may make routine GI diagnostic procedures as simple as swallowing a vitamin pill-sized encapsulated unit in the not-too-far future, and the present reality is that these units are becoming valuable adjuncts to traditional diagnostics. Capsule endoscopy (enteroscopy...

New Assays to Detect Disseminated Fungal Infections

Contributing Editor Harvard Medical School The yeast ) and pulmonary hypersensitivity (<...

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of everyday medications, and in many cases is due to individual gen...

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

Harvard Medical School Contributing Editor Atherosclerosis is the fundamental process in coronary artery disease, stroke, and many other vascular diseases. It is responsible for more than half of the disease burden of the United States, with an annual cost of over $100 billion. This includes over 1.5 million my...

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

New Information on the Potential of Plasmin Shared at ISTH Congress

RESEARCH TRIANGLE PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 - New information representing the continuing research anddevelopment program for Plasmin (Human), TAL-05-00018, waspresented by Talecris Biotherapeutics, Inc.(http://www.talecris.com) this week at the XXIst InternationalSociety for Thrombosis and Haemostasis (ISTH) Congress in Geneva,Switzerland. The information includ...

Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease

DENVER--(BUSINESS WIRE)--Jul 10, 2007 - Corgenix MedicalCorporation (OTC BB: CONX) and the Company's clinical collaboratorsreported new clinical data demonstrating a significant correlationbetween serum levels of the Company's patented AtherOx(TM)bio-markers and cardiovascular disease. The data was presented atthe XXIst Congress of the International Society on Thrombosis andHemostasis (ISTH...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Results fromthe primary analysis of a randomized, controlled, open-label, Phase3 study showed that 77 percent of treatment-experienced HIV-1infected adults taking PREZISTA(TM) (darunavir) 600 mg tablets with100 mg ritonavir (PREZISTA/r) twice daily, plus an optimizedbackground regimen (OBR) of antiretroviral (ARV) agents, reached aplasma v...

New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV

Phase III clinical trial provides hope that HIV patients can livelonger lives PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A newinvestigational drug used in combination with a second newer agenthas proven to be effective in fighting drug-resistant HIV,according to a Lancet article to be published in its July 7thspecial HIV/AIDS issue. The multinational phase III clinical trial,...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...

New Proof of Genistein's Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals ofInternal Medicine has published the results of a two-year clinicalstudy on the impact of genistein on bone loss. The paper, "Effectsof the Phytoestrogen Genistein on Bone Metabolism in OsteopenicPostmenopausal Women-A Randomized Trial," appears in the currentissue (June 19, 2007) and details the safety and efficacy ofgenistein for...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 24, 2007 – Novo Nordisk today announcedresults of a new study that further demonstrated the safety andefficacy of insulin Levemir® (insulin detemir [rDNA origin]injection). Patients with Type 2 diabetes were able to adjusttheir own dosage of Levemir® and achieve improvements i...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Women Report Partner's Symptoms Negatively Affect Relationship BOCA RATON, Fla., June 25, 2007 /PRNewswire/ -- Results of a newnationwide survey show that more than half of women whose malepartners have symptoms of a medical condition known as lowtestosterone incorrectly attribute them to the normal course ofaging. The survey also found that, while women believe their malepartner's sympto...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisktoday announced results of a new study that further demonstratedthe safety and efficacy of insulin Levemir(R) (insulin detemir[rDNA origin] injection). Patients with type 2 diabetes were ableto adjust their own dosage of Levemir(R) and achieve improvem...

New Report 'Looking at Chiral Technologies' Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research andMarkets (http://www.researchandmarkets.com/reports/c60415) hasannounced the addition of Looking at Chiral Technologies to theiroffering. The advancements in molecular research and continued untiringefforts of the research industry to develop better more preciselyapplicable Pharmaceuticals as well as agro compounds would have not...

PromegaExpress Expands Easy Access to Products with New Cabinet

MADISON, Wis.--(BUSINESS WIRE)--Jun 21, 2007 - ThePromegaExpress(TM) on-site stocking program just added a newlysized ambient cabinet to its line of on-site appliances. Thislatest addition serves as great option to meet individual labinventory requirements for smaller areas when space is at a premiumbut immediate access to life science tools is a necessity. Themid-sized cabinet can also be...

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Women's Health Initiative Data

Fourth Study to Indicate that Early Use of Estrogen May beCardio-Protective PHOENIX, June 20, 2007 /PRNewswire-USNewswire/ -- A new analysisof Women's Health Initiative data published in the New EnglandJournal of Medicine, shows significant reduction in calcifiedplaque for women aged 50 to 59 using hormone therapy (HT) comparedwith women taking a placebo. This is the first time therelati...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

SemBioSys to present new data at American Diabetes Association annual meeting

TSX symbol: SBS CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSysGenetics Inc. , a biotechnology company developing a portfolio oftherapeutic proteins for metabolic and cardiovascular disease,today announced that it will be presenting a scientific poster andabstract at the 67th Scientific Sessions of the American DiabetesAssociation (ADA) in Chicago. The Company's poster will disc...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. today announced that data featuring itsapproved diabetes drugs, BYETTA(R) (exenatide) injection andSYMLIN(R) (pramlintide acetate) injection, and its pipelinecandidates will be presented at the American Diabetes Association's(ADA) 67th Annual Scientific Sessions being held in Chicago, ILfrom June 22 to 26. The...

Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron

BILLERICA, Massachusetts --- June20, 2007 --- Millipore Corporation today announced the release ofnew data concerning its ReNcell neural stem cell lines. Theresearch was conducted by the Department of Physiology atUniversity College London and ReNeuron Group plc, whose ReNcelldistribution agreement with Millipore was announced in 2006. The data will be presen...

Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs

BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - Array BioPharmaInc. (Nasdaq: ARRY) announced new Phase 1 clinical data on its MEKinhibitor, ARRY-162, and its p38 inhibitor, ARRY-797. These resultswere presented at the Annual European Congress of Rheumatology(EULAR) in Barcelona, Spain, and at the International Associationof Inflammation Societies' (IAIS) 8th World Congress onInflammation in...

New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

RIDGEFIELD, Conn., June 18, 2007 /PRNewswire/ -- Today, resultsfrom AMADEO*, one of a series of studies comparing two angiotensinreceptor blockers (ARBs) in hypertensive patients with diabeticnephropathy, were presented at the 17th annual European Meeting onHypertension in Milan, Italy. The randomized, double-blind, forced titration, parallel group,multicenter study included 860 hy...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of thefirst studies to compare the protective potential of twoangiotensin receptor blockers in hypertensive patients withdiabetic nephropathy, was presented at the European Societyof Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extentthan losartan.(1)...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosedpre-clinical data showing how a new flu vaccine has the potentialto protect against all strains of influenza, including pandemic andannual, was presented today by PepTcell, at the 2007 Options forthe Control of Influenza VI (Options) Conference, in Toronto,Canada. The pre-cli...

Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI)has presented pre-clinical data for the 57-57 project at the 8thWorld Congress on Inflammation (<a target="_blank" href="http://www.inflammation2007.dk/">www.inflammation2007.dk ) heldin Copenhagen June 16-20*. "The results strengthen the further clinical development of57-57 for the treatment of SLE and show the possib...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Data Presented at Leading Influenza Conference HIGH WYCOMBE, England, June 18, 2007 /PRNewswire/ -- Previouslyundisclosed pre-clinical data showing how a new flu vaccine has thepotential to protect against all strains of influenza, includingpandemic and annual, was presented today by PepTcell, at the 2007Options for the Control of Influenza VI (Options) Conference, inToronto, Canada....

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...